Virpax Pharmaceuticals Stock Today

VRPX Stock  USD 1.28  0.17  11.72%   


0 of 100

Very Weak

Odds Of Distress

Over 85

Very High
Virpax Pharmaceuticals is trading at 1.28 as of the 19th of July 2024; that is 11.72 percent decrease since the beginning of the trading day. The stock's open price was 1.45. Virpax Pharmaceuticals has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Virpax Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 19th of June 2024 and ending today, the 19th of July 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
17th of February 2021
Health Care
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. The company has 2.74 M outstanding shares of which 36.63 K shares are at this time shorted by private and institutional investors with about 0.16 trading days to cover. More on Virpax Pharmaceuticals

Moving together with Virpax Stock

  0.62VKTX Viking Therapeutics Earnings Call This WeekPairCorr
  0.87BMY Bristol Myers Squibb Earnings Call This WeekPairCorr

Moving against Virpax Stock

  0.8PTCT PTC TherapeuticsPairCorr
  0.74INCY IncytePairCorr
  0.72PFE Pfizer Inc Aggressive PushPairCorr
  0.7LLY Eli LillyPairCorr
  0.62MDGL Madrigal PharmaceuticalsPairCorr
  0.44GERN GeronPairCorr

Virpax Stock Highlights

CEO DirectorGerald Bruce
Thematic IdeaPharmaceutical Products (View all Themes)
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Pharmaceutical Products, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Total Current Liabilities8.1 M7.7 M
Sufficiently Up
Slightly volatile
Total Assets12.7 M9.6 M
Significantly Up
Slightly volatile
Total Current Assets12.7 M9.6 M
Significantly Up
Slightly volatile
Debt Levels
Virpax Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Virpax Pharmaceuticals' financial leverage. It provides some insight into what part of Virpax Pharmaceuticals' total assets is financed by creditors.
Virpax Pharmaceuticals currently holds 7.69 M in liabilities with Debt to Equity (D/E) ratio of 0.11, which may suggest the company is not taking enough advantage from borrowing. Virpax Pharmaceuticals has a current ratio of 11.6, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Virpax Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.

Issuance Of Capital Stock

Virpax Pharmaceuticals (VRPX) is traded on NASDAQ Exchange in USA. It is located in 1055 Westlakes Drive, Berwyn, PA, United States, 19312 and employs 7 people. Virpax Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 3.51 M. Virpax Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 2.74 M outstanding shares of which 36.63 K shares are at this time shorted by private and institutional investors with about 0.16 trading days to cover. Virpax Pharmaceuticals currently holds about 26.06 M in cash with (9.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Virpax Pharmaceuticals Probability Of Bankruptcy
Ownership Allocation
Virpax Pharmaceuticals has 6.25 % of its outstanding shares held by insiders and 0.04 % owned by institutional holders.
Check Virpax Ownership Details

Virpax Stock Institutional Holders

InstituionRecorded OnShares
Ubs Group Ag2024-03-31
Renaissance Technologies Corp2024-03-31
Geode Capital Management, Llc2024-03-31
Jpmorgan Chase & Co2024-03-31
Blackrock Inc2024-03-31
Advisor Group Holdings, Inc.2024-03-31
Two Sigma Securities, Llc2024-03-31
Pnc Financial Services Group Inc2023-12-31
100.9 K
Vanguard Group Inc2023-12-31
66.3 K
Tower Research Capital Llc2024-03-31
1.4 K
Signature Resources Capital Management, Llc2024-03-31
View Virpax Pharmaceuticals Diagnostics

Virpax Pharmaceuticals Historical Income Statement

At this time, Virpax Pharmaceuticals' Net Interest Income is fairly stable compared to the past year. Total Other Income Expense Net is likely to rise to about 1.8 M in 2024, whereas Interest Expense is likely to drop slightly above 126.5 K in 2024. View More Fundamentals

Virpax Stock Against Markets

Virpax Pharmaceuticals Corporate Management

Additional Tools for Virpax Stock Analysis

When running Virpax Pharmaceuticals' price analysis, check to measure Virpax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Virpax Pharmaceuticals is operating at the current time. Most of Virpax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Virpax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Virpax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Virpax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.